Mar­ket­ingRx: Bio­gen's new CEO talks DTC for de­pres­sion drug can­di­date; Ab­b­Vie de­buts Skyrizi TV ad for Crohn’s

New Bio­gen CEO Chris Viehbach­er is al­ready look­ing ahead to mar­ket­ing and ad­ver­tis­ing strate­gies for zu­ra­nolone, Bio­gen’s ma­jor de­pres­sive dis­or­der and post­par­tum can­di­date with part­ner Sage Ther­a­puet­ics now await­ing an FDA de­ci­sion, ac­cord­ing to an­a­lysts at SVB Se­cu­ri­ties.

In a note last week, SVB an­a­lysts de­tailed a meet­ing with a “forth­com­ing” Viehbach­er in ear­ly Jan­u­ary in which he talked about zu­ra­nolone’s po­ten­tial launch, among oth­er top­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER